Hyaluronan Inhibitor Development Service at CD BioGlyco

Hyaluronan is a polysaccharide found naturally in human tissues that plays an essential role in the intercellular matrix for structural support and tissue lubrication. However, too much hyaluronan may in some cases lead to the development of inflammation and other diseases. CD BioGlyco has been engaged in Glycosylation Inhibitor Development in recent years and is committed to providing our clients with professional hyaluronan inhibitor development services. We provide our clients with hyaluronan inhibitor development services based on the biosynthesis pathways, which are broadly categorized into the following directions:

• UDP-Glucosidase inhibitor
  The synthesis of hyaluronan is usually dependent on the key enzyme UDP-glucosidase. Based on this, we provide UDP-glucosidase inhibitor development services and investigate methods to utilize them to block the reaction in which UDP-glucose binds to N-acetylglucosamine to form hyaluronan.
• Hyaluronan synthase inhibitors
  Hyaluronan synthase is an important enzyme involved in the synthesis of hyaluronan. We offer hyaluronan synthase inhibitor development services to help you control the synthesis of hyaluronan.
• Glycosyltransferase inhibitors
  N-Acetylglucosamine glucosyltransferase is the key glycosyltransferase that catalyzes the binding of UDP-glucose to N-acetylglucosamine to form the repeating unit of hyaluronan. Therefore, we blocked the activity of N-acetylglucosamine glucosyltransferase by designing and developing glycosyltransferase inhibitors to inhibit the process of hyaluronan synthesis.

Fig.1 How do we conduct the development of hyaluronan inhibitors? (CD BioGlyco)

Applications

• Hyaluronan inhibitors reduce the production of hyaluronan in the joints, thereby reducing joint pain and inflammation, and are therefore used in drug development related to joint inflammation.
• Hyaluronan is strongly associated with tumor growth and metastasis, and hyaluronan inhibitors are used in the development of cancer research.
• Hyaluronan can act as a component of drug delivery systems based on its molecular structure, and the inhibitors may be used to modulate drug delivery and release.

Frequently Asked Questions

• What is the structure of hyaluronan?
  Hyaluronan consists of alternating linkages of N-acetylglucosamine and glucuronic acid. Specifically, the basic unit of hyaluronan is a disaccharide repeating unit of N-acetylglucosamine and glucuronic acid, which are linked together by 1,3-beta- and 1,4-beta-glycosidic bonds to form a linear polysaccharide chain. In terms of chemical structure, hyaluronan is a polyhydroxy acid that contains several hydroxyl groups, and these hydroxyl groups make hyaluronan highly hydrophilic and hydroscopic.
• What is the biosynthetic pathway of hyaluronan?
  Glucosamine and gluconic acid are the precursors for hyaluronan synthesis and they are first taken up and metabolized by the cells. The key enzymes for the synthesis of hyaluronan are three different enzymes, which are UDP-glucosaminyltransferase (UDP-GlcNAc transferase), UDP-glucose carboxyltransferase (UDP-GlcA transferase), and hyaluronan synthase. UDP-GlcNAc transferase and UDP-GlcA transferase are responsible for converting glucosamine and gluconic acid into UDP-N-acetylglucosamine and UDP-N-acetylgluconic acid, which are key steps in hyaluronan synthesis. Hyaluronan synthase then stitches together UDP-N-acetylglucosamine and UDP-N-acetylgluconic acid to form long-chain hyaluronan molecules.

Fig.2 Hyaluronan signaling cascades. (Kobayashi, et al., 2020)

Publication

• Technology: Antitumor effects of the hyaluronan inhibitor 4-methylumbelliferone on pancreatic cancer
• Journal: Oncology letters
• IF: 3.1
• Published: 2016
• Abstract: The main focus of this paper is on the antitumor effects of the hyaluronan inhibitor 4-methylumbelliferone on pancreatic cancer. The study examines the inhibitory effect of 4-methyl stiboglucoside on the growth and metastasis of pancreatic cancer cells in experimental animal models and in vitro experiments, as well as its possible mechanism of action. This includes the effect of the drug on hyaluronan synthesis and the mechanism by which it affects tumor growth and metastasis by regulating hyaluronan levels.
• Method: The human pancreatic cancer cell line MIA PaCa-2 and mice were used as models, along with a range of reagents and materials. The experiments included cell culture, particle rejection assay, immunohistochemical staining, hyaluronan synthesis assay, cell growth and cytotoxicity assay, tumor growth assay, hyaluronan synthesis assay in pancreatic cancer tissues, immunohistochemical staining, and transmission electron microscopy observation. The results of the experiments were statistically analyzed. The application of these experimental methods helps researchers to understand the function and mechanism of action of hyaluronan in pancreatic cancer.

CD BioGlyco provides specialized hyaluronan inhibitor development services covering the full range of support from drug screening to preclinical research. By partnering with us, you will receive the most competitive hyaluronan inhibitor development services to help accelerate your research in related fields. Please feel free to contact us for additional information.